Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, The Lancet, vol.378, issue.9791, pp.571-83, 2011. ,
DOI : 10.1016/S0140-6736(11)61097-0
Estimating the size of the population of persons who inject drugs in the island of Montr??al, Canada, using a six-source capture???recapture model, Drug and Alcohol Dependence, vol.142, pp.174-80, 2014. ,
DOI : 10.1016/j.drugalcdep.2014.06.022
Le volet montréalais du Réseau SurvUDI, Données au 31 mars 2011 Montréal (QC): Direction de santé publique ?Agence de la santé et des services sociaux de Montréal, 2013. ,
Physicians??? Attitudes and Practice Toward Treating Injection Drug Users Infected with Hepatitis C Virus: Results from a National Specialist Survey in Canada, Canadian Journal of Gastroenterology, vol.25, issue.3, pp.135-144, 2011. ,
DOI : 10.1155/2011/810108
Determinants of Antiviral Treatment Initiation in a Hepatitis C-infected Population Benefiting from Universal Health Care Coverage, Canadian Journal of Gastroenterology, vol.21, issue.6, pp.355-61, 2007. ,
DOI : 10.1155/2007/576765
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-65, 2001. ,
DOI : 10.1016/S0140-6736(01)06102-5
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.347, issue.13, pp.975-82, 2002. ,
DOI : 10.1056/NEJMoa020047
Identification of numerous hepatitis C virus genotypes in Montreal, Canada, J Clin Microbiol, vol.34, issue.11, pp.2815-2823, 1996. ,
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013. ,
DOI : 10.1056/NEJMoa1214853
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.20, pp.1889-98, 2014. ,
DOI : 10.1056/NEJMoa1402454
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, New England Journal of Medicine, vol.370, issue.20, pp.1879-88, 2014. ,
DOI : 10.1056/NEJMoa1402355
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.16, pp.1483-93, 2014. ,
DOI : 10.1056/NEJMoa1316366
ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, vol.370, issue.21, pp.1973-82, 2014. ,
DOI : 10.1056/NEJMoa1402869
Retreatment of HCV with ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, vol.370, issue.17, pp.1604-1618, 2014. ,
DOI : 10.1056/NEJMoa1401561
The principles of disease elimination and eradication, Bull World Health Organ, vol.76, issue.2, pp.22-27, 1998. ,
Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements, Clinical Infectious Diseases, vol.57, issue.7, pp.1014-1034, 2013. ,
DOI : 10.1093/cid/cit377
The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis, PLoS ONE, vol.46, issue.5, p.101554, 2014. ,
DOI : 10.1371/journal.pone.0101554.s002
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs, Hepatology, vol.8, issue.Suppl 1, pp.1090-101, 2016. ,
DOI : 10.1002/hep.28227
Modelling hepatitis C transmission over a social network of injecting drug users, Journal of Theoretical Biology, vol.297, pp.73-87, 2012. ,
DOI : 10.1016/j.jtbi.2011.12.008
Approximate Bayesian computational methods, Statistics and Computing, vol.6, issue.31, pp.1167-80, 2012. ,
DOI : 10.1007/s11222-011-9288-2
URL : https://hal.archives-ouvertes.fr/hal-00567240
An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver, Canadian Journal of Gastroenterology and Hepatology, vol.29, issue.1, pp.19-34, 2015. ,
DOI : 10.1155/2015/692408
Recommendations for testing, managing, and treating hepatitis C. 2014. [Accessed, 2015. ,
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study, CMAJ Open, vol.4, issue.4, pp.605-619, 2016. ,
DOI : 10.9778/cmajo.20160008
Liste de médicaments, 2015. ,
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention, PLoS ONE, vol.375, issue.7, p.103345, 2014. ,
DOI : 10.1371/journal.pone.0103345.s004
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam, Journal of Hepatology, vol.51, issue.4, pp.667-74, 2009. ,
DOI : 10.1016/j.jhep.2009.05.027
Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales, BMC Infectious Diseases, vol.330, issue.1, p.93, 2006. ,
DOI : 10.1136/bmj.38286.841227.7C
The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs, Hepatology, vol.138, issue.Suppl 1, pp.1861-70, 2014. ,
DOI : 10.1002/hep.27403
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia, The Medical Journal of Australia, vol.196, issue.10, pp.638-679, 2012. ,
DOI : 10.5694/mja11.10981
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals, Hepatology, vol.42, issue.5, pp.1598-609, 2013. ,
DOI : 10.1002/hep.26431
Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy, Clinical Infectious Diseases, vol.57, issue.suppl 2, pp.39-45, 2013. ,
DOI : 10.1093/cid/cit296
Access to Sterile Injecting Equipment is More Important Than Awareness of HCV Status for Injection Risk Behaviors Among Drug Users, Substance Use & Misuse, vol.61, issue.1, pp.548-68, 2009. ,
DOI : 10.1016/S0376-8716(00)00144-7
Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness, Addictive Behaviors, vol.37, issue.4, pp.552-557, 2012. ,
DOI : 10.1016/j.addbeh.2011.12.001
Health care costs associated with hepatocellular carcinoma: A population-based study, Hepatology, vol.50, issue.4, pp.1375-84, 2013. ,
DOI : 10.1002/hep.26231
Using social networks to better conceptualize risk fro bloodborne viruses among injection drug users. Montréal: McGill university, 2007. ,
Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience, Drug and Alcohol Dependence, vol.102, issue.1-3, pp.1-3158, 2009. ,
DOI : 10.1016/j.drugalcdep.2009.01.006
Mortality in a Cohort of Street Youth in Montreal, JAMA, vol.292, issue.5, pp.569-74, 2004. ,
DOI : 10.1001/jama.292.5.569
Institut National d'Excellence en Santé et Services Sociaux pour la mise à jour des listes de médicaments, 2015. ,
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C, Hepatology, vol.20, issue.1, pp.15-20, 1994. ,
Analysis of duration of risk behaviour for key populations: a literature review, Sexually Transmitted Infections, vol.88, issue.Suppl 2, pp.24-32, 2012. ,
DOI : 10.1136/sextrans-2012-050647